← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

SS-31 × NAD+ × 2 of 4 selected View comparison

SS-31

Mitochondria-targeting tetrapeptide

Remove
VS

NAD+

Cellular redox cofactor

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target SS-31NAD+
✓ —
— ✓

What These Compounds Share

No direct target, secondary target, pathway tag, or research area is shared by all selected compounds — see Key Differences below. This reflects the structured data as recorded, not an absence of any conceivable relationship.

Key Differences

SS-31 CARDIOLIPIN is a direct target of SS-31 that none of the other selected compounds share. Directly targets mitochondrial membrane biology via cardiolipin interaction.
NAD+ NAD+ is a direct target of NAD+ that none of the other selected compounds share. A cellular cofactor rather than a receptor-targeting peptide -- the only non-peptide, non-small-molecule compound in this catalogue.

Compound Detail

SS-31
What is it?
A peptide designed to target and support mitochondria, the energy factories inside cells.
What are people researching/using it for?
Studied for mitochondrial health, especially in heart and muscle tissue.
Other uses being trialed
Age-related energy declineExercise recovery research
Worth knowing
Human trials have shown mixed results across different conditions studied.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Preferentially localises to mitochondria and interacts with cardiolipin, with research into mitochondrial membrane organisation and energetics.
Synthetic aromatic-cationic tetrapeptide · 4 amino acids · Synthetic
Also known as: Elamipretide, MTP-131
Primary Targets & Biological System
Inner mitochondrial membrane biology

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
An aromatic-cationic peptide that, due to its charge and structure, preferentially concentrates in the inner mitochondrial membrane rather than acting on a surface receptor. There it binds cardiolipin -- a phospholipid unique to mitochondrial membranes that helps organise the protein complexes mitochondria use to produce energy. By stabilising cardiolipin's interaction with these complexes, research has investigated SS-31's effects on mitochondrial respiratory efficiency and reduction of damaging reactive oxygen species, particularly in tissues with high energy demand like heart and skeletal muscle.
Research Areas
Mitochondrial dysfunctionMitochondrial energeticsCardiolipin biologySkeletal muscleCardiac mitochondrial biologyMitochondrial disease
Research Profile
Human administration: Available Preclinical: Extensive
Pharmacokinetics
Not displayed as a single universal value across the routes studied.
Research Routes
Subcutaneous, Intravenous (descriptive only — not administration or dosing guidance)
Key Differentiator
Directly targets mitochondrial membrane biology via cardiolipin interaction.
Considerations
Research Limitations
Human trials have shown mixed results across different conditions studied.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Barth syndrome
A phase 2/3 randomized trial showed meaningful improvement in a 6-minute walk test and cardiac function over 48 weeks. As of September 2025, the FDA granted accelerated approval (brand name FORZINITY) for Barth syndrome specifically -- the first approved therapy for any mitochondrial disease. This is a genuine approval, but narrow: for this one rare genetic condition, not a general endorsement.
Primary mitochondrial myopathy
An earlier trial (MMPOWER-2) showed a dose-dependent improvement in walk distance, but the larger phase 3 MMPOWER-3 trial (218 adults) did not meet its primary endpoints -- no significant improvement in walk distance or fatigue versus placebo. Included here specifically because the result was negative, not to imply a positive outcome.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
SS-31 · A$239.95 A$299.95
Browse products →
View Research Sources (4) →
Mechanistic source on cardiolipin/mitochondrial membrane biology (1)
Preclinical (animal) · PMID 32273339

Supports: mechanism_summary

Mechanistic source on cardiolipin/mitochondrial membrane biology (2)
Preclinical (animal) · PMID 24134698

Supports: mechanism_summary

Mechanistic source on cardiolipin/mitochondrial membrane biology (3)
Preclinical (animal) · PMID 23813215

Supports: mechanism_summary

Human clinical example
Human Human · PMID 28916603

Supports: human_administration_status

NAD+
What is it?
A natural molecule every cell needs to make energy and repair itself.
What are people researching/using it for?
Studied for cellular energy, ageing biology and general vitality research.
Other uses being trialed
DNA repair supportMitochondrial health
Worth knowing
Direct administered-NAD+ human research is considerably more limited than research on precursors (NR/NMN) -- those findings are not transferred to NAD+ itself here. A small human pilot study (8 IV-NAD+ participants, 3 controls) has directly measured plasma/urinary NAD+ metabolite changes during a 6-hour infusion -- real human PK-adjacent data, but from a small sample and without an efficacy endpoint.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A cellular redox cofactor central to electron transfer, NAD+/NADH reactions, and as a substrate for sirtuins and PARP enzymes.
Dinucleotide / coenzyme -- not a peptide · Endogenous
Primary Targets & Biological System
Cellular energy / redox metabolism

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
NAD+ is not a signalling molecule that binds a receptor -- it is a coenzyme every cell uses directly in metabolism, shuttling electrons in the reactions that generate cellular energy (the NAD+/NADH redox couple). It also serves as a required substrate for two enzyme classes: sirtuins, involved in various regulatory cellular processes, and PARP enzymes, involved in DNA repair. Because it is consumed as a substrate rather than acting as a switch, its effects are tied to overall cellular NAD+ availability rather than a conventional single-target dose-response.
Research Areas
Cellular energeticsMitochondrial biologyRedox metabolismDNA repair biologyAge-associated NAD metabolism
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
No universal half-life value is displayed for this cofactor.
Research Routes
Intravenous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A cellular cofactor rather than a receptor-targeting peptide -- the only non-peptide, non-small-molecule compound in this catalogue.
Considerations
Research Limitations
Direct administered-NAD+ human research is considerably more limited than research on precursors (NR/NMN) -- those findings are not transferred to NAD+ itself here. A small human pilot study (8 IV-NAD+ participants, 3 controls) has directly measured plasma/urinary NAD+ metabolite changes during a 6-hour infusion -- real human PK-adjacent data, but from a small sample and without an efficacy endpoint.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Addiction / withdrawal support
IV NAD+ is widely marketed at private clinics for opioid and alcohol withdrawal, with some small studies reporting reduced craving/withdrawal scores. Addiction researchers have specifically cautioned that this evidence is weak -- much of it traces back to research from the 1960s with roughly 100 participants -- and that withdrawal-symptom relief is not the same as addiction recovery. Treat this as a heavily-marketed but thinly-evidenced use, not an established one.
Infusion tolerability (real-world clinic data)
A retrospective review of a commercial IV-therapy clinic's own records (four consecutive days of 500 mg IV NAD+) reported moderate-to-severe infusion-related symptoms (GI upset, increased heart rate, chest pressure) that resolved by the end of each infusion, plus some lab-value changes. This is real-world tolerability data, not a controlled efficacy trial -- and the authors are employees of the commercial IV-wellness company whose clients were reviewed, a disclosed conflict of interest worth weighing.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
NAD+ · A$159.95 A$179.95
Browse products →
View Research Sources (2) →
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
Frontiers in Aging Neuroscience, 2019 · Human Human · 11 male participants (8 NAD+, 3 saline control), aged 30-55 · Intravenous · PMID 31572171 · DOI 10.3389/fnagi.2019.00257

Measured plasma and urinary NAD+, nicotinamide, ADPR, methylnicotinamide and NMN at multiple timepoints. Real human PK-adjacent data on administered NAD+ itself, but a small pilot with no efficacy endpoint.

Supports: mechanism_summary, research_limitations

Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
Frontiers in Aging, 2026 · Human Human · Retrospective EMR review of commercial IV-therapy clinic clients · Intravenous · PMID 41704678 · DOI 10.3389/fragi.2026.1652582

Reported moderate-to-severe infusion-related GI symptoms, increased heart rate and chest pressure during infusions (resolved by end of infusion), longer infusion times than nicotinamide riboside, and some lab-value changes (ALP decrease, HDL-C reduction). Real-world tolerability data, not a controlled efficacy trial. Authors are employees of the commercial IV-wellness company whose clients were reviewed -- a disclosed conflict of interest.

Supports: experimental_research

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.